The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Fulcrum Therapeutics Inc shares valued at $1,831 were sold by Tourangeau Greg on May 07 ’24. At $7.76 per share, Tourangeau Greg sold 236 shares. The insider’s holdings dropped to 11,571 shares worth approximately $95460.75 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Tourangeau Greg sold 4,884 shares, netting a total of over 57,219 in proceeds. Following the sale of shares at $11.72 each, the insider now holds 11,807 shares.
Before that, Sapir Alex had added 43,360 shares to its account. In a trade valued at $492,028, the insider bought Fulcrum Therapeutics Inc shares for $11.35 each. Upon closing the transaction, the insider’s holdings increased to 43,360 shares, worth approximately $0.36 million.
As published in their initiating research note from Cantor Fitzgerald on May 20, 2024, Fulcrum Therapeutics Inc [FULC] has been an Overweight and the price target has been revised to $23. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid March. As of September 25, 2023, Goldman has initiated its “Neutral” rating for FULC. Earlier on August 23, 2023, H.C. Wainwright upgraded its rating. Their new recommendation was “a Buy” for FULC stock which previously was a “a Neutral”.
Analyzing FULC Stock Performance
During the last five days, there has been a drop of approximately -6.83%. Over the course of the year, Fulcrum Therapeutics Inc shares have jumped approximately 22.22%. Shares of the company reached a 52-week high of $13.70 on 03/06/24 and a 52-week low of $5.68 on 06/26/24. A 50-day SMA is recorded $8.23, while a 200-day SMA reached $7.82. Nevertheless, trading volume fell to 0.59 million shares from 0.76 million shares the previous day.
Support And Resistance Levels for Fulcrum Therapeutics Inc (FULC)
According to the 24-hour chart, there is a support level at 7.98, which, if violated, would cause prices to drop to 7.72. In the upper region, resistance lies at 8.52. The next price resistance is at 8.80. RSI (Relative Strength Index) is 44.36 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.72, which suggests the price will decrease in the coming days. Percent R is at 85.84%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
